United States Últimas notícias

AbbVie (NYSE:ABBV) has secured authorization from the European Commission for an expanded label of its oncology drug VENCLYXTO (venetoclax) to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).

The former Chair of Société Générale, Lorenzo Bini Smaghi, has stepped down after more than a decade at the helm. Bini Smaghi says he leaves the lender with 'best in class' governance and a share price 60% higher than when he joined. But he added that the restructuring is not fully over and there are big deals to come. Bini Smaghi joined Lizzy Burden on 'The Pulse'.

Lowe’s Companies (NYSE:LOW) authorized a 4% increase to its quarterly cash dividend, extending a multi-decade track record of annual payout increases and signaling confidence in its steady cash generation capabilities.

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.

Federal Reserve Bank of Kansas City President Jeff Schmid said officials should make it clear they're willing to do what is needed to achieve price stability. "We must continue to signal our commitment to price stability and our willingness to take the actions necessary to achieve our mandate," Schmid said Friday at a conference in Reykjavík, Iceland.

The Buckle (NYSE:BKE) reported a significant increase in first-quarter profitability, driven by steady brick-and-mortar sales growth and an injection of cash from a finalized legal settlement.

International Flavors & Fragrances (NYSE:IFF) agreed to sell its Food Ingredients division to funds advised by CVC Capital Partners in a transaction valuing the unit at approximately $4.3 billion.

Genesco (NYSE:GCO) reported first-quarter revenue that surpassed Wall Street expectations, driven by a modest recovery in brick-and-mortar retail traffic that countered stagnant growth across its e-commerce segments.

Merck (NYSE:MRK) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its investigational oral drug calderasib when paired with the company’s blockbuster immunotherapy Keytruda, accelerating its development path for newly diagnosed lung cancer patients.

Noah Holdings (NYSE:NOAH) reported a sharp acceleration in operating profitability for the first quarter of 2026, as a structural rebound in domestic wealth management clients and stringent cost controls offset flat revenues and equity asset volatility.

Chagee Holdings (NASDAQ:CHA) reported a rise in first-quarter revenue as aggressive international expansion partially offset cooling demand in its home market, though a sharp contraction in operating margins drove net income down by more than a third.